Background: Visfatin is an adipokine that is highly expressed in visceral fat. Plasma levels of visfatin have been reported to be higher in subjects with obesity and/or type 2 diabetes mellitus. However, the role of visfatin in endothelial dysfunction has been largely unexplored. Objectives: We investigated the possible pathogenic role of visfatin in endothelial dysfunction, particularly focusing on its effect on inflammatory mediators. Design: Primary human umbilical vein endothelial cells (HUVECs) pretreated with visfatin (1, 10 and 50 ng ml À1 ) were used to study the relationship between visfatin and endothelium dysfunction. Expressions of adhesion molecules (ICAM-1, VCAM-1 and E-selectin) and cytokines (interleukin (IL)-6 and IL-8) affected by visfatin were investigated by enzyme-linked immunosorbent assay, flow cytometry and real-time PCR. Activity of nuclear factor (NF)-kB was examined by electrophoretic mobility shift assay. Results: At a visfatin concentration of 50 ng ml À1 , significant increases in IL-6, IL-8, ICAM-1, VCAM-1 and E-selectin gene expression along with increased IL-6, IL-8 and sE-selectin protein levels in the conditioned medium were detected. Flow cytometry showed that the addition of visfatin significantly increased ICAM-1 expression and VCAM-1 expression (10 and 50 ng ml À1 , respectively). Electrophoretic mobility shift assay confirmed that visfatin increased the DNA-binding activity of NFkB. In addition, pretreatment with visfatin (10 and 50 ng ml À1 ) increased human monocyte cell line THP-1 adhesion to HUVECs. Conclusions: Our findings suggest that visfatin causes endothelial dysfunction by increasing inflammatory and adhesion molecule expression at least partly through the upregulation of NF-kB activity.
Introduction
Obesity has increased to epidemic proportions in industrialized nations 1 and is an independent risk factor for cardiovascular diseases. 2 Recent studies have indicated that adipokines, secreted from adipocytes, influence lipid and glucose metabolism as well as modulate the inflammatory processes of atherosclerosis. 3, 4 Adipokines have also been found to be expressed within atherosclerotic plaques, suggesting the local and endocrine effects of these mediators on atherosclerotic lesions. 5, 6 Visfatin is a recently discovered visceral-fat-specific adipokine that is predominantly produced in visceral adipose tissue, 7 particularly by the macrophages. 8 Both its tissue expression and secreted plasma concentrations increase in parallel with obesity. 7, 9 In addition, visfatin has insulinmimetic properties and exerts hypoglycemic effect both in vitro and in vivo. 7 Elevated plasma visfatin concentrations have been reported in subjects with type 2 diabetes mellitus. 10 Visfatin can also be considered as a proinflammatory adipokine because it has been observed in inflammatory cells as well as in a variety of inflammatory conditions. 11, 12 Visfatin has also been reported to upregulate the production of cytokines interleukin (IL)-1b, IL-6 and tumor necrosis factor-a in vitro and in vivo. 12 Therefore, visfatin could represent an additional link between adipose tissue and inflammation. 13 Emerging evidence has established a potential link between adipokines and vascular dysfunction.
14 Visfatin is highly expressed in macrophages within human unstable atherosclerotic lesions, and has been proposed to potentially play roles in atherosclerotic plaque destabilization. 15 Furthermore, plasma visfatin concentrations have recently been reported to be negatively associated with flow-mediated vasodilatation, an in vivo measure of vascular endothelial function, in patients with type 2 diabetes mellitus. 16 However, the detailed cellular mechanisms between visfatin and human endothelial functions remain undetermined. Herein, we investigated the possible pathogenic role of visfatin in endothelial dysfunction, particularly focusing on its role in inflammation and adhesion molecule expression as well as the subsequent adhesion of human monocytes. 
Materials and methods

Materials
Cell cultures
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord with collagenase and used at passages 2-3. 17 Human umbilical cords were obtained from pregnant women with normal delivery who had no hepatitis, acquired immune deficiency syndrome or other contagious diseases. This study has been approved by a local ethical committee, and written informed consent was obtained from all of the subjects before the collection of the umbilical cords. After dissociation, the cells were collected and cultured on gelatin-coated culture dishes in M199 with low serum growth supplement, 100 IU ml À1 penicillin and ) for 24 h. The collected culture-conditioned medium was centrifuged to separate floating cells in the medium, and the supernatant was stored at À80 1C.
Commercially available enzyme-linked immunosorbent assay kits were used to measure levels of IL-6, IL-8, sICAM-1, sVCAM and sE-selectin in the conditioned medium, according to the manufacturers' directions. The optical density was measured at 450 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA), and the cytokine concentration was calculated relative to the IL-6, IL-8, sICAM-1, sVCAM-1 and sE-selectin standards.
Flow cytometry of ICAM-1, VCAM-1 and E-selectin expression on the endothelial cell surface To determine whether visfatin could induce adhesion molecule expression, HUVECs at a density of 1 Â 10 5 cells per well were seeded in 6-cm 0.2% gelatin-coated dishes with complete medium and incubated at 37 1C in 5% CO 2 for 3 days. The medium was removed and treated with visfatin (1, 10 and 50 ng ml
À1
) for 24 h. At the end of stimulation, the cells were detached from the dishes and washed. The cell suspension was centrifuged, the supernatant was discarded and the pellet was resuspended. These cells were then stained by adding fluorescein isothiocyanate-conjugated mouse anti-human ICAM-1, VCAM-1 and E-selectin antibodies for 30 min at room temperature. After the cells were washed three times, immunofluorescence intensity was analyzed using flow cytometry with a Becton Dickinson FACScan (Mountain View, CA, USA).
Total RNA isolation and real-time PCR To investigate the effects of visfatin on inflammation and adhesion gene expression in endothelial cells, we placed HUVECs in the M199 without the addition of growth factor for 16 h (serum starvation). Serum-starved HUVECs were treated with visfatin (10 and 50 ng ml
) and incubated for 4 h. Total RNA was isolated from the HUVECs using TRIzol reagent. Reverse transcription was performed at 42 1C for 60 min and followed by incubation at 95 1C for 5 min. The reaction mixture (20 ml of total volume) consisted of 2 mg of isolated total RNA, 1 mM of dNTP, 1 U ml À1 of recombinant RNasin ribonuclease inhibitor, 15 U mg À1 of avian
Visfatin-induced expression of inflammatory mediators W-J Lee et al myeloblastosis virus reverse transcriptase, 5 Â RT buffer and 0.5 mg of oligo(dT) 12 primer. Real-time PCRs were performed with the SYBR Green method in an ABI 7000 sequence detection system (Applied Biosystems, Foster City, CA, USA) following the manufacturer's guidelines. Human IL-6, IL-8, ICAM-1, VCAM-1 and E-selectin as well as b-actin primers were designed using the computer software Primer Express 2.0 (Applied Biosystems). The gene-specific primers used are as follows: IL-6 sense: 5 0 -TACCCCCAGGAGAAGATTCC-3 0 ; IL-6 antisense: 5 0 -TTTTCTGCCAGTGCCTCTTT-3 0 ; IL-8 sense:
The reactions were set by mixing 12.5 ml of the SYBR Green Master Mix (Applied Biosystems) with 1 ml of a solution containing 10 mmol l À1 of both primers and 2 ml of a cDNA solution. The C t value was defined as the number of PCR cycles where the fluorescence signal exceeded the detection threshold value. The relative amount of mRNA for each gene was normalized based on that of the housekeeping gene b-actin.
Electrophoretic mobility shift assays
To investigate the effects of visfatin on nuclear factor (NF)-kB activation in endothelial cells, we treated HUVECs with visfatin (1, 10 and 50 ng ml
À1
) for 1 h. Afterwards, HUVECs were gently harvested and washed twice with ice-cold phosphate-buffered saline containing 0.3 mM phenylmethanesulfonylfluoride, and the nuclear fraction was extracted from the cell pellet of the cells using an NE-PER nuclear and cytoplasmic reagent. Ten micrograms of the nuclear fraction was incubated at 30 1C for 30 min in the presence of poly (dI-dC) with double-stranded NF-kB consensus oligonucleotides labeled at the 3 0 -terminal by biotin. The following consensus probe for NF-kB was used: 5 0 -AGTTGAGGGGACTTTCCCA GGC-3 0 . The samples were separated on 6% polyacrylamide gel electrophoresis and then transferred to a nitrocellulose membrane by electroblotting. After incubation with streptoavidin conjugated to horseradish peroxidase (1:5000), peroxidase activity was detected using an enhanced chemiluminescence substrate system.
Adhesion assay
Human umbilical vein endothelial cells at a density of 1 Â 10 5 cells per ml were cultured in 96-well flat-bottom plates (0.1 ml per well) for 1-2 days. Cells were treated with visfatin (1, 10 and 50 ng ml
À1
) and incubated for 24 h. Medium was removed and 0.1 ml per well of THP-1 cells (pre-labeled with 2,7 bis-(2-carboxyethyl)-5-(and-6)carboxyfluorescein, acetoxymethyl ester 4 mM for 30 min in RPMI at a density of 1 Â 10 6 cell per ml) was added to RPMI. Cells were allowed to adhere at 37 1C for 1 h in a 5% CO 2 incubator. Nonadherent cells were gently aspirated. Plates were washed three times with M199. The number of adherent cells was estimated by microscopic examination, and then lysed with 0.1 ml of 0.25% Triton X-100. The fluorescence intensity was measured at 485 nm excitation and 538 nm emission using a fluorescence microplate reader (Labsystems, San Diego, CA, USA).
Statistical analyses
All experiments were performed on at least three occasions in triplicate. Results are expressed as mean ± s.d. Data were analyzed using the Mann-Whitney U-test for significant difference. Statistical significance was assumed for P-values o0.05. All data analyses were performed with the SPSS 10.0 software package.
Results
Effect of visfatin on IL-6, IL-8, sICAM-1, sVCAM-1 and sE-selectin production from HUVECs In cell culture experiments, the addition of visfatin did not affect the cell number or the cell viability, as indicated by cell morphology and methylthiazol tetrazolium tests (data not shown). To understand the effect of visfatin on cytokine and adhesion molecule production, we treated HUVECs with visfatin for 24 h, whereupon cytokine and soluble adhesion molecule levels secreted into the medium were measured. Compared with the control, HUVECs incubated in the presence of 10 and 50 ng ml À1 visfatin showed significant increases in the release of IL-6 (95.9 ± 12.0 and 120.0±12.5 pg ml
À1
, respectively, vs 67.9±6.5 pg ml
, both Po0.05) and IL-8 (639.9±16.3 and 643.2±70.3 pg ml À1 , respectively, vs 520.7 ± 40.8 pg ml À1 , both Po0.05) (Figures   1a and b) . However, visfatin had no effect on the expression of sICAM-1 and sVCAM-1 when compared with the control (Figures 1c and d) . There was also a significant increase (482.9 ± 71.3 vs 270.3 ± 75.3 pg ml
, Po0.05) in the expression of sE-selectin in response to the addition of 50 ng ml À1 visfatin (Figure 1e ).
Visfatin-induced ICAM-1 and VCAM-1 expression at the vascular surface
The effects of visfatin on the surface expression of adhesion molecules in HUVECs were further examined by flow cytometry analysis. Results from these experiments showed that the amount of HUVECs expressing ICAM-1 increased (111.9 ± 1.9 vs 100 ± 0%, Po0.01) in response to the addition of 10 ng ml À1 visfatin, and the amount of HUVECs expressing VCAM-1 increased (106.0±5.6 vs 100±0%, Po0.05) in response to the addition of 50 ng ml À1 visfatin (Figures 2a   and b) . However, visfatin did not enhance E-selection expression (data not shown).
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Visfatin-induced gene expression of cytokines and adhesion molecules in HUVECs
To examine whether visfatin could stimulate cytokine and adhesion gene expression in HUVECs, we treated cells with two different concentrations (10 and 50 ng ml
À1
) of visfatin for 4 h and then processed the cells for the analysis of cytokine and adhesion molecule mRNA using real-time PCR. We found that a higher dose (50 ng ml À1 ) of visfatin treatment caused significant increases (Po0.05) in the levels of IL-6 (2.72-fold), IL-8 (1.93-fold), ICAM-1 (1.71-fold), VCAM-1 (3.97-fold) and E-selectin (2.80-fold) gene expression in endothelial cells (Figure 3 ).
Visfatin increased NF-kB activity in HUVECs
We hypothesized that visfatin could induce cytokine and adhesion molecule gene expression through NF-kB activation. Results of electrophoretic mobility shift assay experiments showed that HUVECs treated with visfatin (10 and 50 ng ml
À1
) induced a significant increase in NF-kB activation (156.1 ± 9.8 and 138.4 ± 11.3%, respectively, Po0.05), as shown in Figure 4 .
Visfatin-induced adherence of THP-1 cells to HUVECs Pretreatment of HUVECs with visfatin (10 and 50 ng ml
À1
) for 24 h significantly increased THP-1 cell adhesion (122.5 ± 6.3 and 122.7 ± 6.8%, respectively, Po0.05), as shown in Figure 5 .
Discussion
The main findings from our experiments were that visfatin enhanced the expression of the adhesion and inflammatory proteins, sICAM-1, sVCAM-1, sE-selectin, IL-6 and IL-8, and Visfatin-induced expression of inflammatory mediators W-J Lee et al increased the mRNA expression of these proteins, possibly through the activation of NF-kB activity.
Although the detailed mechanism of visfatin on obesity remains largely undetermined, recent studies have indicated that visfatin directly binds to the insulin receptor, resulting in tyrosine phosphorylation as well as phosphorylation of insulin receptor substrate-1 and -2, leading to an enhanced glucose uptake in vitro and in vivo. 7 This suggests a possible role for visfatin production as a compensatory response in diet-or obesity-induced insulin resistance. 6 In fact, elevated plasma visfatin levels have been reported in subjects with type 2 diabetes mellitus. 10 As the effects of insulin on endothelial cell function and the overall physiology of the vasculature have been well documented, 18 it is, therefore, legitimate to assume that visfatin would affect the vascular endothelium.
The expression of adhesion molecules such as VCAM-1 and ICAM-1 on the endothelial cell surface is the initial step in atherogenesis. 19 Circulating levels of sVCAM-1 and sICAM-1 were reported to be directly associated with obesity and other coronary heart disease risk factors and might serve as predictors of coronary heart disease. 20 In this study, we demonstrated that visfatin enhanced ICAM-1 and VCAM-1 expression in endothelial cells. In line with our findings, Axelsson et al. 21 observed that visfatin was associated independently with level of serum sVCAM-1, a marker of endothelial damage, in patients with chronic kidney disease. In addition, visfatin has been reported to upregulate cell surface expression of costimulatory molecules CD54 (ICAM-1), CD40 and CD80 in human monocytes. 12 We also found that visfatin enhances the expression of endothelium-related adhesion molecules, such as sE-selectin. After cell activation, selectin molecules are rapidly removed from the cell surface by a mechanism of internalization and lysosomal targeting (P-and E-selectin) or by shedding/proteolytic cleavage (L-and E-selectin). Overexpression or maintenance of these molecules may have critical effects on inflammation and on the integrity of the vascular wall.
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Both IL-6 and IL-8 have been reported to be involved in the pathogenesis of obesity, insulin resistance and atherosclerosis. 23, 24 Our findings indicate a visfatin-induced endothelial production of IL-6 and IL-8, which is in agreement with a recent study showing that visfatin induced the production of cytokines IL-1b, IL-6 and tumor necrosis factor-a in vitro and in vivo. 12 Interestingly, another study reported that IL-6 reciprocally suppressed visfatin expression in 3T3-L1 adipocytes, demonstrating the complex relationship between these two proteins. 25 Monocyte-endothelium interaction is crucial in the initial stage of atherogenesis. 26 In this study, we observed an increase in the adherence of THP-1 cells to HUVECs, which might result from visfatin-induced increased expression of the adhesion molecules ICAM-1, VCAM-1 and E-selectin. Although the increases in these adhesion molecule expression elicited by visfatin were modest, such changes possibly contributed to increased atherosclerosis risk. An enhanced expression of ICAM-1, VCAM-1 and E-selectin has been reported in human atherosclerotic plaques and was associated with increased leukocyte recruitment and accumulation. 27, 28 Many cytokines and cell-adhesion molecules can induce gene expression through NF-kB activation. 29 Results from Visfatin-induced expression of inflammatory mediators W-J Lee et al our study demonstrated that visfatin upregulated NF-kB activity, indicating that visfatin induced inflammatory and adhesion molecule expression possibly through the NF-kB signaling pathway. In accordance with our results, recent reports showed that visfatin increased NF-kB p65 (RelA) DNA-binding capacity in human monocytes 12 and also enhanced the expression of adhesion molecules ICAM-1 and VCAM-1 through reactive oxygen species-dependent NF-kB activation in human microvascular endothelial cells. 30 In addition, Adya et al. 31 demonstrated that visfatin induced matrix metalloproteinase-2/9 mRNA expression and gelatinolytic activity through NF-kB signaling in a human endothelial cell line. NF-kB activity can be modulated through phosphorylation by mitogen-activated protein kinases, including extracellular signal-regulated kinase 1/2, JNK and p38. It has been shown that the inhibition of the Visfatin-induced expression of inflammatory mediators W-J Lee et al p38 mitogen-activated protein kinase abrogated visfatininduced cytokine production in monocytes 12 and visfatin promoted angiogenesis through the activation of the extracellular signal-regulated kinase 1/2 in endothelial cells. 32 Therefore, visfatin-induced NF-kB activation might be partly through the phosphorylation of mitogen-activated protein kinase pathway. A recent study demonstrated that the inhibition of visfatin-induced activation of phosphatidylinositol 3-kinase/Akt and extracellular signal-regulated kinase 1/2 pathways led to a significant decrease in visfatin-induced matrix metalloproteinase and vascular endothelial growth factor production, along with a significant reduction in endothelial proliferation and capillary tube formation. 33 Our experiments assessed both adhesion molecule expression and monocyte adhesion to endothelial cells using in vitro models. Such models have been widely used to assess the effects of exogenous treatment on the early and essential step in atherogenesis. [34] [35] [36] However, whether these in vitro models accurately reflect in vivo processes remains to be determined. We studied the effects of visfatin without the addition of other factors commonly found in the serum. Although this allows for a more accurate determination of the individual effect of visfatin, these conditions do not reflect the complex circulating environment in vivo.
In conclusion, our findings suggest that visfatin causes endothelial dysfunction by increasing the mRNA expression of adhesion and inflammatory molecules, ICAM-1, VCAM-1, E-selectin, IL-6 and IL-8, and subsequent protein levels, probably through activation of the NF-kB pathway.
